Pat Toomey: “Your bill directly addresses concerns about the harmful impact of prescription drug fraud and abuse on the health and…”

I think that there are a number of ways that you can go about creating a regulatory regime to take account of that risk.

Congress can and should offer a sensible approach for the domestic regulation of these activities.

I think there is a case to be made that there should be a regulatory regime on disclosure requirements for an issuer.

As I've said before, Government, and especially this Administration, have often been the problem, not the solution, when it comes to housing.